AVIR Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the re…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Atea (AVIR) Q2 2026 Earnings Call Transcript HCV regimen met non-inferiority with 8-week dosing for non-cirrhotic patients. | ||
 Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary Moby summary of Atea Pharmaceuticals, Inc.'s Q2 2026 earnings call | ||
 Atea Pharmaceuticals Q2 Earnings Call Highlights Atea Pharmaceuticals (NASDAQ:AVIR) reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa. | ||
 FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result. | ||
 Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial Atea Pharmaceuticals Inc. announced on Tuesday positive topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis C virus infection. The C-BEYOND study enrolled 905 patients and met its primary... | ||
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial Atea Pharmaceuticals (AVIR) said Tuesday a pivotal phase 3 trial of its experimental combination the | ||